- Home
- EQR vs DGX Comparison
EQR vs DGX Comparison
Compare EQR & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- DGX
- Stock Information
- Founded
- EQR 1993
- DGX 1967
- Country
- EQR United States
- DGX United States
- Employees
- EQR N/A
- DGX N/A
- Industry
- EQR Real Estate Investment Trusts
- DGX Medical Specialities
- Sector
- EQR Real Estate
- DGX Health Care
- Exchange
- EQR Nasdaq
- DGX Nasdaq
- Market Cap
- EQR 24.7B
- DGX 20.5B
- IPO Year
- EQR 1993
- DGX 1996
- Fundamental
- Price
- EQR $64.81
- DGX $180.82
- Analyst Decision
- EQR Buy
- DGX Buy
- Analyst Count
- EQR 12
- DGX 15
- Target Price
- EQR $76.13
- DGX $185.40
- AVG Volume (30 Days)
- EQR 1.8M
- DGX 698.2K
- Earning Date
- EQR 10-29-2025
- DGX 10-21-2025
- Dividend Yield
- EQR 4.23%
- DGX 1.77%
- EPS Growth
- EQR 5.58
- DGX 12.66
- EPS
- EQR 2.65
- DGX 8.35
- Revenue
- EQR $3,044,764,000.00
- DGX $10,522,000,000.00
- Revenue This Year
- EQR $4.90
- DGX $11.12
- Revenue Next Year
- EQR $4.00
- DGX $3.41
- P/E Ratio
- EQR $24.69
- DGX $21.68
- Revenue Growth
- EQR 4.40
- DGX 12.58
- 52 Week Low
- EQR $59.41
- DGX $146.17
- 52 Week High
- EQR $78.84
- DGX $185.62
- Technical
- Relative Strength Index (RSI)
- EQR 47.19
- DGX 52.42
- Support Level
- EQR $65.56
- DGX $179.77
- Resistance Level
- EQR $67.11
- DGX $185.05
- Average True Range (ATR)
- EQR 1.10
- DGX 2.58
- MACD
- EQR 0.03
- DGX -0.28
- Stochastic Oscillator
- EQR 36.47
- DGX 46.94
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.